Larimar Therapeutics, Inc. aksje
LRMR
Sanntid$3.3350-0.1750 (-4.99%)
Laster graf...
Larimar Therapeutics, Inc.
Market Cap
$346,449,600
Åpning3.4700
Høy3.4800
Lav3.3100
Volum1.22M
P/EN/A
Markedsverdi346.45M
52-ukers høy6.4200
52-ukers lav2.1500
Gj.sn. volum1.83M
UtbytteN/A
Beta0.91
EPS-2.1200
Om Larimar Therapeutics, Inc. aksje
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Selskapsinformasjon
Børs: NasdaqGM (NGM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
Three Bala Plaza East
19004 Bala Cynwyd, United States
19004 Bala Cynwyd, United States
Telefon: + 844 511 9056
Nettside: https://www.larimartx.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Anbefaling:1.20 - Stærk køb
Laveste kursmål
7.00
↑ 109.9%
Gjennomsnittlig kursmål
15.11
↑ 353.1%
Median kursmål
13.00
↑ 289.8%
Høyeste kursmål
26.00
↑ 679.6%